Akero Therapeutics (AKRO) stock was upgraded by Bank of America based on Phase 2 data the company shared for its liver disorder drug, efruxifermin. Read more here.

Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) traded up 4.8% during mid-day trading on Wednesday after Morgan ...

BofA analyst Jason Zemansky upgraded Akero Therapeutics (AKRO) to Buy from Neutral with a $63 price target Invest with Confidence: Follow ...

Why have drugs to treat the liver disease MASH reached a tipping point? How did Hims & Hers convince Childish Gambino to ...

In a recent SEC filing, Rolph Timothy, Chief Scientific Officer of Akero Therapeutics, Inc. (NASDAQ:AKRO), disclosed the sale of company shares valued at approximately $1.74 million. The transactions, ...

Jefferies analyst Michael Yee increased the price target for Akero Therapeutics stock, listed on (NASDAQ:AKRO), to $75 from ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Akero's success in reversing cirrhosis follows that of Madrigal, making analysts and investors bullish on drugs to treat ...

Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. See why I continue to rate ETNB stock a buy.

Josh Sheluk, portfolio manager at Verecan Capital Management Inc., shares his tips on how investors can navigate the fragility of a concentrated market.